RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
WeDoctor, an online healthcare platform, closed a $500 million pre-IPO funding at a $5.5 billion valuation. WeDoctor, which is part of TenCent, China’s giant internet company, is expected to list on the Hong Kong exchange later this year with a goal of raising $1 billion. The latest round was led by AIA Group, a medical insurance company, and NWS Holdings. AIA will become the preferred insurance provider for the site.
Source: China Biotoday
